Stay updated on Obeldesivir Study in High-risk COVID-19: Clinical Trial
Sign up to get notified when there's something new on the Obeldesivir Study in High-risk COVID-19: Clinical Trial page.

Latest updates to the Obeldesivir Study in High-risk COVID-19: Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2; no substantive changes to the study details, locations, or eligibility criteria are visible on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedThe PubMed publications note is updated to say publications are automatically filled from PubMed and may not be about the study. The page revision shows Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved the government funding notice stating information may not be up to date and that the NIH Clinical Center is open. It also directed users to opm.gov for operating status updates.SummaryDifference0.2%

- Check43 days agoChange DetectedOnly minor, non-substantive edits such as formatting tweaks and small textual corrections are visible. The core study details, including the intervention, outcomes, eligibility, and site information, appear unchanged.SummaryDifference0.3%

- Check71 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference3%

- Check79 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Obeldesivir Study in High-risk COVID-19: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Obeldesivir Study in High-risk COVID-19: Clinical Trial page.